SEPRAFILM(TM) (HAL-F(TM)) BIORESORBABLE MEMBRANE
FDA premarket approval P950034/S001 · decided 1996-11-07
Approval details
- PMA number
- P950034
- Supplement
- S001
- Supplement type
- Real-Time Process
- Supplement reason
- Change Design/Components/Specifications/Material
- Trade name
- SEPRAFILM(TM) (HAL-F(TM)) BIORESORBABLE MEMBRANE
- Generic name
- Barrier, absorbable, adhesion
- Applicant
- Baxter Healthcare Corporation
- Date received
- 1996-10-22
- Decision date
- 1996-11-07
- Days to decision
- 16 days
- Decision code
- APPR
- Product code
- MCN
- Advisory committee
- General, Plastic Surgery
- Expedited review
- No
- Location
- Deerfield Lake, IL
- Statement
- CHANGE IN THE CURRENT HA/CMC SPECIFICATION FOR THE UREA ASSAY FROM THE CURRENT 3 - 15% TO A SPECIFICATION OF 10-18% FOR THE MODIFIED ASSAY. THE SUPPLEMENT ALSO REQUESTS THE REPLACEMENT OF THE USP RABBIT PYROGEN ASSAY WITH THE LIMULUS AMOEBOCYTE LYSATE (LAL) ASSAY AS THE STANDARD PYROGEN TEST
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.
510(k) clearances by this applicant
| Record | Firm | Date |
|---|---|---|
| Welch Allyn FlexiPort Blood Pressure Cuffs (FlexiPort Blood Pressure Cuffs) (K251745) | Baxter Healthcare Corporation | 2025-12-16 |
| SIGMA Spectrum Infusion Pump with Master Drug Library (K251640) | Baxter Healthcare Corporation | 2025-07-28 |
| Spectrum IQ Infusion System with Dose IQ Safety Software (3570009) (K251636) | Baxter Healthcare Corporation | 2025-07-28 |
| Solution Administration Sets (K243529) | Baxter Healthcare Corporation | 2025-03-14 |
| Intravascular Extension Sets and Accessories (K242339) | Baxter Healthcare Corporation | 2025-02-28 |
| Novum IQ Syringe Pump (40800BAXUS) (K242390) | Baxter Healthcare Corporation | 2024-09-05 |
| Actifuse ABX; Actifuse MIS; Actifuse Shape; ALTAPORE; ALTAPORE SHAPE; ALTAPORE MIS (K241564) | Baxter Healthcare Corporation | 2024-08-02 |
| Novum IQ Large Volume Pump (K211122) | Baxter Healthcare Corporation | 2024-03-29 |